150 related articles for article (PubMed ID: 21521014)
1. SNPs in ERCC1 and drug response to cisplatin in non-small-cell lung cancer patients.
Osawa K
Pharmacogenomics; 2011 Apr; 12(4):445-7. PubMed ID: 21521014
[No Abstract] [Full Text] [Related]
2. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
3. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
[TBL] [Abstract][Full Text] [Related]
4. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
[TBL] [Abstract][Full Text] [Related]
6. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
Cobo M; Isla D; Massuti B; Montes A; Sanchez JM; Provencio M; Viñolas N; Paz-Ares L; Lopez-Vivanco G; Muñoz MA; Felip E; Alberola V; Camps C; Domine M; Sanchez JJ; Sanchez-Ronco M; Danenberg K; Taron M; Gandara D; Rosell R
J Clin Oncol; 2007 Jul; 25(19):2747-54. PubMed ID: 17602080
[TBL] [Abstract][Full Text] [Related]
7. Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients.
Park SY; Hong YC; Kim JH; Kwak SM; Cho JH; Lee HL; Ryu JS
Med Oncol; 2006; 23(4):489-98. PubMed ID: 17303907
[TBL] [Abstract][Full Text] [Related]
8. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients.
Chen S; Huo X; Lin Y; Ban H; Lin Y; Li W; Zhang B; Au WW; Xu X
Int J Hyg Environ Health; 2010 Mar; 213(2):140-5. PubMed ID: 20189873
[TBL] [Abstract][Full Text] [Related]
9. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
10. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Zhou W; Gurubhagavatula S; Liu G; Park S; Neuberg DS; Wain JC; Lynch TJ; Su L; Christiani DC
Clin Cancer Res; 2004 Aug; 10(15):4939-43. PubMed ID: 15297394
[TBL] [Abstract][Full Text] [Related]
11. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going.
Rosell R; Cuello M; Cecere F; Santarpia M; Reguart N; Felip E; Taron M
Curr Opin Oncol; 2006 Mar; 18(2):135-43. PubMed ID: 16462182
[TBL] [Abstract][Full Text] [Related]
12. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
Olaussen KA; Mountzios G; Soria JC
Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
[TBL] [Abstract][Full Text] [Related]
13. Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non-small-cell lung cancer.
Rosell R; Manegold C; Moran T; Garrido P; Blanco R; Lianes P; Stahel R; Trigo JM; Wei J; Taron M
Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S76-82. PubMed ID: 21885003
[TBL] [Abstract][Full Text] [Related]
14. Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.
He C; Duan Z; Li P; Xu Q; Yuan Y
Anticancer Drugs; 2013 Mar; 24(3):300-5. PubMed ID: 23211354
[TBL] [Abstract][Full Text] [Related]
15. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.
Friboulet L; Olaussen KA; Pignon JP; Shepherd FA; Tsao MS; Graziano S; Kratzke R; Douillard JY; Seymour L; Pirker R; Filipits M; André F; Solary E; Ponsonnailles F; Robin A; Stoclin A; Dorvault N; Commo F; Adam J; Vanhecke E; Saulnier P; Thomale J; Le Chevalier T; Dunant A; Rousseau V; Le Teuff G; Brambilla E; Soria JC
N Engl J Med; 2013 Mar; 368(12):1101-10. PubMed ID: 23514287
[TBL] [Abstract][Full Text] [Related]
16. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.
Felip E; Rosell R
Expert Rev Mol Diagn; 2007 May; 7(3):261-8. PubMed ID: 17489733
[TBL] [Abstract][Full Text] [Related]
17. [Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy].
Wang J; Zhang Q; Zhang H; Wang Q; Yang X; Gu Y; Zhang S
Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):337-41. PubMed ID: 20677561
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients.
Suk R; Gurubhagavatula S; Park S; Zhou W; Su L; Lynch TJ; Wain JC; Neuberg D; Liu G; Christiani DC
Clin Cancer Res; 2005 Feb; 11(4):1534-8. PubMed ID: 15746057
[TBL] [Abstract][Full Text] [Related]
19. Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer.
Rosell R; Taron M; Barnadas A; Scagliotti G; Sarries C; Roig B
Cancer Control; 2003; 10(4):297-305. PubMed ID: 12915808
[TBL] [Abstract][Full Text] [Related]
20. Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer.
Ikeda S; Takabe K; Suzuki K
Pathol Int; 2009 Dec; 59(12):863-7. PubMed ID: 20021611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]